SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3 -mediated activation of the Wnt/β-catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α-SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis [1].
In Vivo, SNX3-IN-1 (Compound LC4) (10 mg/kg; intratracheal administration; once weekly for 3 consecutive weeks) effectively ameliorates Wnt/β-catenin pathway activation, pulmonary function impairment and fibrosis in a mouse model of pulmonary fibrosis[1].
In Vitro, SNX3-IN-1 (Compound LC4) inhibits the enhanced migratory capacity of fibroblasts overexpressing SNX3[1]. SNX3-IN-1 inhibits SNX3-induced β-catenin accumulation and nuclear localization in cells[1]. SNX3-IN-1 (10 μM) inhibits TGF-β1-induced α-SMA expression in AT2 cells and fibroblasts, thereby reducing fibrotic activation[1].
References:
[1]. Ma D, et al. Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling. Cell Death Dis. 2026;17(1):43. Published 2026 Jan 15.
In Vivo, SNX3-IN-1 (Compound LC4) (10 mg/kg; intratracheal administration; once weekly for 3 consecutive weeks) effectively ameliorates Wnt/β-catenin pathway activation, pulmonary function impairment and fibrosis in a mouse model of pulmonary fibrosis[1].
In Vitro, SNX3-IN-1 (Compound LC4) inhibits the enhanced migratory capacity of fibroblasts overexpressing SNX3[1]. SNX3-IN-1 inhibits SNX3-induced β-catenin accumulation and nuclear localization in cells[1]. SNX3-IN-1 (10 μM) inhibits TGF-β1-induced α-SMA expression in AT2 cells and fibroblasts, thereby reducing fibrotic activation[1].
References:
[1]. Ma D, et al. Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling. Cell Death Dis. 2026;17(1):43. Published 2026 Jan 15.